Abstrak 
Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients
Franky Chandra, Oki Suwarsa, Dendi Sandiono, Hendra Gunawan, Unwati Sugiri
Universitas Padjadjaran, Dermatol Ther (Heidelb) (2017) 7:133–141 DOI 10.1007/s13555-016-0163-0, open access at Springerlink.com
Bahasa Inggris
Universitas Padjadjaran, Dermatol Ther (Heidelb) (2017) 7:133–141 DOI 10.1007/s13555-016-0163-0, open access at Springerlink.com
: Cutaneous side effects, Epidermal growth factor receptor inhibitor, Transepidermal water loss
Introduction: Cutaneous side effects caused by epidermal growth factor receptor (EGFR) inhibitors occurred in 45–100% of patients which may lead to therapy modification or interruption. This study aimed to evaluate cutaneous side effects and transepidermal water loss (TEWL) values in non-small cell lung carcinoma (NSCLC) patients who received gefitinib EGFR inhibitor. Methods: A descriptive observational study with cross-sectional design and a consecutive sampling method was conducted from 1 February to 4 March 2016. Eleven NSCLC patients with EGFR mutation who visited the Hemato-Oncology Clinic/Internal Medicine Department, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, were assessed through history taking, physical examination, and TEWL examination using Tewameter. Results: Ten of the eleven patients experienced cutaneous side effects. The most frequently observed was xerosis cutis (8/10 patients), followed by acneiform eruptions (7/10 patients), and paronychia (3/10 patients). None of these patients experienced hair changes, mucositis, or drug hypersensitivity. Mean TEWL value of these patients was higher than normal (11.205 ± 1.881 g/m 2 /h).Conclusions: Patients who received gefitinib EGFR inhibitor experienced cutaneous side effects including xerosis cutis, acneiform eruptions, and paronychia, and have mean TEWL values higher than normal. Therefore, it might affect the skin barrier function.